

MANHATTAN PHARMACEUTICALS INC  
Form 8-K  
May 01, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 28, 2006

**Manhattan Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**    **001-32639**    **36-3898269**  
(State or    (Commission    (IRS  
other    File Number)    Employer  
jurisdiction of  
incorporation)    Identification  
No.)

**810 Seventh Avenue, 4th Floor**                      **10019**  
(Address of principal executive                      (Zip Code)  
offices)

**(212) 582-3950**  
(Registrant's telephone number, including area code)

**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On April 28, 2006, Manhattan Pharmaceuticals, Inc. issued a press release announcing the status of the development of its product candidates Oleoyl-estrone and PTH(1-34). The press release is attached to this Current Report as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits. The following exhibit is filed herewith.

| <u>Exhibit<br/>No.</u> | <u>Description</u>                  |
|------------------------|-------------------------------------|
| 99.1                   | Press release dated April 28, 2006. |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MANHATTAN PHARMACEUTICALS,  
INC.**

Date: May 1, 2006

By: /s/ Nicholas J.  
Rossettos  
Nicholas J. Rossettos  
Chief Financial Officer

---

**EXHIBIT INDEX**

| <b><u>Exhibit</u></b> | <b><u>Description</u></b>           |
|-----------------------|-------------------------------------|
| <b><u>No.</u></b>     |                                     |
| 99.1                  | Press release dated April 28, 2006. |